MedTrace Logo

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

NCT00160043 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2014-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

SH T00268C

1250 mg experimental drug od

DRUG

PTK787/ ZK 222584

1250 mg experimental drug bid (500mg + 750mg)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-08-31
Completion
2008-11-30

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160043 on ClinicalTrials.gov